



Patient Card

Carry this card with you at all times.
SHOW THIS CARD to any healthcare
professional involved in your care and
if you go to the hospital

Fold here

TECVAYLI® can cause side effects such as cytokine release syndrome (CRS) and neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), which may be serious, life-threatening, or fatal.¹

Patient's name:

Fold here

Important Safety Information FOR THE PATIENT

Get medical help straight away if you experience any of the following:¹

Symptom of Cytokine Release Syndrome

- » Fever (38°C or higher)
- » Chills
- » Fast heartbeat
- » Difficulty breathing
- » Nausea
- » Headache
- » Feeling dizzy

Symptom of Neurologic toxicity, including ICANS

- » Headache
- » Confusion
- » Hearing loss
- » Trouble speaking, reading, and writing
- » Slower and jerking movements
- » Problems walking
- » Changes in handwriting
- » Muscle weakness or rigid muscles
- » Feeling restless and tremor
- » Numbness and tingling and burning pain
- » Personality changes, e.g., being less talkative, disinterest in activities

Fold here

IMPORTANT TO REMEMBER:

Stay close to the location where you received your TECVAYLI® therapy for at least 2 days for daily monitoring after administration of your first three doses (usually two step-up doses and first maintenance dose).

If you have any of the symptoms listed on this card, call your doctor, or seek emergency medical attention right away. These are not all the possible side effects of TECVAYLI®. Tell your doctor if you have any symptom that bothers you or does not go away.

Treating Physician

Treating physician's
name:

Treating physician's
phone number:

Hospital name and address:

Hospital phone number:

Fold here

Information for Healthcare Team to fill in

Please give this card to your healthcare team to fill in the information and return to you.

Dates of TECVAYLI® injections (step-up dosing schedule):

Step-up dose 1: _____

Step-up dose 2: _____

First maintenance dose* _____

*This is the first full treatment dose (1.5 mg/kg)

Fold here

Important Safety Information FOR HEALTHCARE PROFESSIONALS

CRS, including life-threatening or fatal reactions, and neurologic toxicities including ICANS may occur in patients receiving TECVAYLI®.¹ The majority of CRS and neurologic toxicities including ICANS observed following TECVAYLI® administration were Grade 1 and 2.¹ Assess the patient for signs and symptoms of CRS and neurologic toxicities including ICANS. If your patient reports any signs or symptoms as referenced on this card, please contact the patient's treating physician immediately for further information.

Scan the QR code for
local approved Package Insert.



Fold here

References

1. J&J Singapore. TECVAYLI® Solution for Injection Package Insert (HSA approved)

TECVAYLI® Patient Card Version 1.
This document has been approved by HSA as of 16 Feb 2024